Policy & Regulation
Limbix Raises USD 15m in Series A2 Financing, Bringing Total Funding to USD 31m
7 December 2021 - - US-based prescription digital therapeutic company Limbix has raised USD 15m in series A2 financing from both existing and new investors, bringing total funding to date to USD 31m, the company said.

The round was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink and DN Capital.

The round also includes investments from Korean Investment Partners, E and Investment, Gaingels, MVP, Operator Partners, Mana Ventures and Pacific Health Ventures.

Last month, Limbix launched SparkRx, the first digital therapeutic for adolescents with symptoms of depression.

The SparkRx program is based on core principles of cognitive behavioral therapy with a focus on behavioral activation and is delivered to patients via smartphone.

Limbix also recently announced positive results from a clinical trial of SparkRx, which demonstrated a statistically significant reduction in depression symptoms, compared to an active control, for users who completed the program as recommended.

Capital raised in the financing will be used by Limbix for commercialization efforts and to double its staff to approximately 60 employees by 2Q22.

With an expanded product and research team, Limbix plans to accelerate the development and testing of new digital therapeutics targeting other common adolescent mental health disorders.

Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents.

Limbix said its team is uniquely suited to develop prescription digital therapeutics, as its diverse team of clinicians, product designers, researchers, and engineers understand the value of pairing clinical expertise with technological innovation.

Their first digital therapeutic, SparkRx by Limbix, is now available for licensed health care professionals to offer to patients nationwide.
Login
Username:

Password: